{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-26-000014","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2026-08-05T11:33:09+00:00","discovered_at":"2026-08-05T11:35:03.469355+00:00","generated_at":"2026-08-05T11:35:10.479520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance","bullets":["Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).","Raised FY 2026 Portfolio Receipts guidance to $3.4B-$3.5B (from $3.325B-$3.45B).","Acquired royalty on AstraZeneca's cliramitug for up to $425M ($125M upfront) in July.","Capital Deployment YTD $1.1B; announced transactions value $1.7B.","Paid Q2 dividend $0.235/share; repurchased $45M in shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-26-000014","json":"https://secwatch.observer/filing/0001802768-26-000014.json","markdown":"https://secwatch.observer/filing/0001802768-26-000014.md","text":"https://secwatch.observer/filing/0001802768-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/0001802768-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:35:10.479520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}